📄 other

RareLens: A Quantitative Framework for Identifying Research Funding Disparities in Rare and Autoimmune Diseases Relative to Patient Burden

The paper introduces RareLens, an open-access quantitative framework that reveals significant disparities between NIH research funding and patient burden for rare and autoimmune diseases, demonstrating that over half of the analyzed conditions are underfunded relative to their impact, with Postural Orthostatic Tachycardia Syndrome (POTS) exhibiting the most severe funding gap.

Original authors: Aditi Kishore¹

Published 2026-07-27

📖 5 min read🧠 Deep dive

CC BY 4.0

Original authors: Aditi Kishore¹

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

Imagine the world of medical research as a massive, bustling library. In this library, scientists are the readers, and the books they write are new discoveries about how our bodies work and how to fix them when they break. But here's the catch: the library doesn't have infinite money to buy books. The National Institutes of Health (NIH) acts like the library's head librarian, deciding which diseases get the most "book-buying" money. Usually, the librarian tries to be fair, giving more money to the problems that affect the most people or cause the most pain. However, sometimes the librarian gets distracted, or maybe the books for certain problems are just harder to find, leaving some patients waiting in the dark while others get a spotlight. This is the story of "research funding equity"—a fancy way of asking: Does the money we spend on research match the actual trouble the disease causes for real people?

Enter RareLens, a new digital tool created by a student researcher named Aditi Kishore. Think of RareLens as a super-powered magnifying glass that doesn't just look at one book, but scans the entire library at once. It compares two things for 47 different rare and autoimmune diseases: first, how much "pain" or "burden" the disease causes (how many people have it and how miserable it makes them feel), and second, how much "research" is happening (how much money the NIH is spending and how many new books are being written). By lining these up side-by-side, RareLens calculates a "Gap Score." If the score is high, it means the disease is suffering from a massive neglect—it's a crying baby that the librarian hasn't noticed yet. If the score is zero, it means the research money is perfectly matched to the patient's needs.

The story this paper tells is a bit of a detective tale with a surprising twist. When Aditi used RareLens to scan her list of 47 diseases, she found that the library's distribution of attention was very lopsided. More than half of the diseases (25 out of 47) had a Gap Score of zero, meaning they were getting a fair share of research money relative to their burden. But the other half? They were in a "concentrated tail" of neglect. The most dramatic example of this neglect is a condition called POTS (Postural Orthostatic Tachycardia Syndrome), which affects how your heart rate and blood pressure react when you stand up.

According to the data, POTS has a "Burden Score" of 74 (very high trouble) but a "Research Score" of only 13 (very low attention). This resulted in a Gap Score of 61, the highest on the list. To put this in perspective, the paper reveals that between 2015 and 2026, the NIH gave only $397,440 in identifiable grants for POTS. When you divide that tiny amount by the estimated 562,700 patients in the US, it works out to about $0.35 per patient per year. That's less than the cost of a candy bar to help a whole year's worth of patients. Meanwhile, another condition called Systemic Lupus Erythematosus (SLE) had a Gap Score of 0, receiving a massive $667.7 million in funding, which the paper suggests is a very fair match for its burden.

The paper also highlights a few other "neglected" characters. Ehlers-Danlos Syndrome (hypermobile type), which affects how stretchy and strong your connective tissues are, came in second for neglect with a Gap Score of 40. On the flip side, the paper notes that some diseases often thought to be underfunded, like ME/CFS (Chronic Fatigue Syndrome), actually showed a smaller gap (Score of 18) recently, likely because of a surge in funding related to Long COVID research.

However, the story isn't just about the numbers; it's also about the tools used to find them. The author admits that the "magnifying glass" (RareLens) isn't perfect. For instance, a technical glitch in the library's computer system (an API rate-limiting error) once made it look like a disease called Progressive Supranuclear Palsy (PSP) had zero funding and a terrifyingly high neglect score of 79. A manual check revealed this was a mistake; PSP actually had the most funding in the catalog ($647.5 million). This teaches us that while the tool is powerful, it needs human eyes to double-check the results.

So, what does this all mean? The paper suggests that for many rare and autoimmune diseases, the research funding does not match the patient burden. It identifies specific conditions, like POTS and hEDS, that are being significantly overlooked. It doesn't claim to have solved the problem or proven exactly why the librarian is ignoring these patients (though it guesses that a lack of clear biological "clues" or strong patient advocacy groups might be the reason). Instead, it offers a clear, open, and reproducible way to measure the gap. It's a call to action, handing the community a new map to show where the library's attention needs to shift so that no patient is left waiting in the dark.

Technical Summary: RareLens – A Quantitative Framework for Identifying Research Funding Disparities

Problem Statement
Rare and autoimmune diseases affect an estimated 25 to 30 million Americans, yet research funding for these conditions frequently fails to reflect the burden they impose on patients, families, and healthcare systems. The paper posits a specific hypothesis: National Institutes of Health (NIH) research funding allocations for rare and autoimmune diseases do not align with patient burden. Currently, there is a lack of open, reproducible tools to quantitatively measure this misalignment, making it difficult to advocate for research equity or identify specific areas of neglect.

Methodology
To address this, the author developed RareLens, an open-access platform (web and iOS) that aggregates data from three primary sources: the NIH Reporter API (for funding data from 2015–present), PubMed E-Utilities (for publication volume), and ClinicalTrials.gov (for trial counts). The system calculates three composite percentile rank scores (0–100) for each disease within a reference catalog of 47 conditions (14 autoimmune, 8 neurological, and 25 from other categories).

The scoring framework is defined as follows:

Research Score ( $R$ ): A weighted composite of NIH funding volume and publication count ( $R = \text{round}(0.6 \times \text{fundingRank} + 0.4 \times \text{pubRank})$ ).
Patient Burden Score ( $B$ ): A composite of disease prevalence and inverted quality-of-life (QoL) burden ( $B = \text{round}(0.5 \times \text{prevalenceRank} + 0.5 \times \text{qolBurdenRank})$ ). Prevalence data is sourced from the Orphanet Report Series 2023 or curator estimates; QoL is derived from inverted scores where lower QoL indicates higher burden.
Gap Score ( $G$ ): The primary equity metric, calculated as $G = \text{round}(\max(0, B - R))$ . This score represents the disparity where burden exceeds research attention.

The catalog was curated to include diseases that are rare or documented as underfunded, possess specific NIH search terms, have established patient advocacy organizations, and ensure category diversity. For diseases outside the catalog, the system offers an on-demand scoring feature using AI-assisted metadata estimation when reliable sources are lacking.

Key Results
Application of the framework to the 47-disease catalog revealed a strongly right-skewed distribution of Gap Scores (mean 9.3, median 0, range 0–61).

Distribution: 53% of diseases (25/47) had a Gap Score of 0, indicating research is proportionate to burden. 26% fell into a "Mild Gap" tier, 17% "Moderately Neglected," and 4% "Significantly" or "Severely Neglected."
Highest Neglect: Postural Orthostatic Tachycardia Syndrome (POTS) exhibited the highest Gap Score ( $G=61$ ; $B=74, R=13$ ). Despite an estimated 562,700 US patients, it received only $397,440 in identifiable NIH grants (2015–2026), equating to approximately $0.35 per patient annually. It has no FDA-approved disease-specific treatment.
Second Highest: Hypermobile Ehlers-Danlos Syndrome (hEDS) had the second-highest score ( $G=40$ ), with 662,000 estimated patients and a severe QoL burden, yet received significantly less funding relative to its burden compared to other conditions.
High Alignment: Systemic Lupus Erythematosus (SLE) demonstrated the most proportionate relationship ( $R=95, G=0$ ), supported by $667.7 million in cumulative funding and nine approved therapies.
Anomalies and Corrections: The study noted a technical limitation where an API rate-limiting error initially recorded $0 funding for Progressive Supranuclear Palsy (PSP), falsely inflating its Gap Score to 79. Manual verification corrected this to $647.5 million in funding and a Gap Score of 3. Similar provisional $0 values remain for four other diseases pending verification.

Key Contributions

RareLens Platform: The creation of a reproducible, open-access tool that integrates disparate data sources (NIH, PubMed, ClinicalTrials.gov) to quantify research equity.
Quantitative Gap Metric: The introduction of the Gap Score ( $G$ ) as a standardized measure to identify diseases where patient burden significantly outpaces research investment.
Empirical Evidence of Disparity: The study provides concrete data showing that for a significant subset of rare and autoimmune diseases (e.g., POTS, hEDS), NIH funding is disproportionately low relative to patient prevalence and quality-of-life impact.
Identification of Structural Factors: The analysis highlights that high-gap diseases often share structural characteristics, such as a lack of diagnostic biomarkers, predominantly female patient populations, and recent clinical recognition, which may contribute to underfunding.

Significance and Claims
The paper claims that its findings support the belief that NIH funding does not align with patient burden across the analyzed catalog. By providing an open and reproducible tool, RareLens aims to facilitate advocacy for research equity. The authors note that the framework currently does not account for the strength of patient advocacy groups, which may be a confounding variable in funding allocation. The study emphasizes that while the 47-disease catalog is a non-random sample, the methodology allows for the on-demand scoring of other diseases, offering a scalable approach to monitoring research disparities. The authors explicitly state that the tool is intended to support advocacy efforts and highlight areas where investment may need to be re-evaluated to better match patient needs.

Technical Summary: RareLens – A Quantitative Framework for Identifying Research Funding Disparities

More like this